Head-to-head · Value Score
CoreAge Rx vs MEDGm
Two GLP-1 deals, scored on the same six factors. CoreAge Rx lands a Value Score of 93, MEDGm a 64. Here's who gives you the honest lower price — and where each one bites back.
CoreAge Rx
#1 · Grade A+ · Best Value
Est. first month
$99/mo
Save ~89% vs brand-nameMEDGm
#292 · Grade C · Watch List
Est. first month
$299/mo month-to-month (the $179 headline is the first month only, after an automatic welcome coupon)
Save ~78% vs brand-nameThe verdict
CoreAge Rx takes it on Value Score, 93 to 64 — an est. $99/mo first month, with no teaser step-up baked in. MEDGm isn't out of it: Shoppers who want an oral tablet and an injection from the same desk with four named pharmacies behind them, and who will price month two before month one.
CoreAge Rx is also our overall #1 pick across the whole deals ranking — a flat, all-in price on both molecules in all 50 states. That's why it wins here on the score, not just this matchup.
Deal-by-deal
The numbers that decide it. Green ✓ marks the stronger side on each line.
| Deal | CoreAge Rx | MEDGm |
|---|---|---|
| Value Score | 93 (A+) | 64 (C) |
| Est. first month | $99/mo | $299/mo month-to-month (the $179 headline is the first month only, after an automatic welcome coupon) |
| Save vs brand-name | ~89% | ~78% |
| Semaglutide | $99/mo | $299/mo month-to-month (the $179 headline is the first month only, after an automatic welcome coupon) |
| Tirzepatide | $149/mo | $399/mo month-to-month (the $279 headline is the first month only) |
| Both molecules | Yes | Yes |
| Pricing | Flat — no step-up | Watch |
| Coverage | All 50 states | All 50 states and D.C. |
Factor by factor
The six factors behind each Value Score. The orange bar marks the stronger side. See the methodology.
CoreAge Rx
The honest lowest price: both molecules at one flat, all-in monthly rate that never steps up after month one.
Why it's a deal
- Flat, all-in monthly price with no intro-rate step-ups after month one
- Both compounded semaglutide and tirzepatide on one account
- Available in all 50 states
- Straightforward, low-friction cancellation — no lock-in
The fine print
- Not the rock-bottom sticker — a couple of teaser tiers advertise lower month-one rates
- No FDA-approved brand-name option (compounded only)
- Does not yet publicly name its 503A/B pharmacy partner
MEDGm
Compounded semaglutide at $299 a month and tirzepatide at $399, sold behind a "starting at $179" headline that is a first-month coupon — on a site whose own questions promise the price never increases.
Why it's a deal
- Four dispensing pharmacies are named with street addresses, phone numbers and websites, which is the fullest supply-chain disclosure in this batch
- The full ladder is shown before payment with real totals rather than per-month arithmetic: $747, $1,314 and $2,028 on semaglutide, $1,047, $1,914 and $3,228 on tirzepatide
- An oral dissolving semaglutide tablet is sold alongside the injection at a published $369 a month, so the needle-free route has a price rather than a waiting list
- Coverage is stated as the fifty states and the District of Columbia and matches the intake's own list exactly — no hedge that contradicts the claim, and nothing narrower hidden in the terms
- The prescribing medical groups are named as entities, state by state, and the terms state the auto-renewal mechanics in full rather than leaving them to be discovered
- The company's state of formation and governing law are published, and support has a phone number and an address under the brand
The fine print
- The advertised price is a coupon. "Starting at $179" is $299 with $120 taken off the first month by an automatically applied code; removing the code rewrites the panel to $299 while you watch
- The treatment page's own questions say "your price never increases, even as your dose goes up" on a plan whose price increases by $120 at the first renewal — the sentence is true about the dose and false about the month
- The prepay bundles are charged in full up front and auto-renew into another full term, up to ten days early, unless canceled at least seventy-two hours ahead — so a twelve-month plan can become a second $2,028 or $3,228 charge
- The savings figures printed on the ladder are calculated against the standing rate, which is only ever billed on the month-to-month plan, and the same three figures appear on the oral tab where the standing rate is different
- The headline figures on the treatments card match no number in the ladder directly beneath them
- No clinician is named and no identifier is published — only medical-group entities — and which of the four pharmacies is 503A or 503B, or fills which state, is not stated
- No principal place of business is published anywhere; the only addresses on the site belong to the four pharmacies and a state regulator notice
- The signup prints a clinical match, a success probability of one hundred percent and a headline saying the prescription plan is approved, all before payment and before any clinician has seen the file
- The questions say a candidate is likely suitable at a body mass index of 20 or above, which is inside the normal range
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes a Value Score.
Neither one the right fit? Every program that outscores CoreAge Rx is ranked on the CoreAge Rx alternatives ranking, and the same list for the other side is on alternatives to MEDGm.
More head-to-heads
Prices, states and verification reflect each program's public disclosures at last check; the Value Score is our editorial judgment per the methodology. “Save vs brand-name” compares the lowest disclosed monthly price against a ~$1,349/mo brand-name cash reference. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.